Chemotherapy induced peripheral neuropathy in confirmed diagnosed cancer patients.. Serum neuropathy
Conditions
Interventions
Intervention 1: Intervention group: 140 mg/day of silymarin (Gol Daru Company, Iran) in two daily doses with 300 mg/day Gabapentin as a standard treatment for peripheral neuropathy for 3 month. Both m
Sponsors
Mazandaran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Histologically confirmed diagnosis of cancer At least 18 years of age Having chemotherapy-induced peripheral neuropathy (CIPN).
Exclusion criteria
Exclusion criteria: Having a known disease predisposing to neuropathy, including diabetes, neuromuscular disease, vitamin B12 deficiency, amyloidosis, and connective tissue disease, a history of neurological diseases such as hereditary and acquired neuropathies Unbearable side effects of the drug or drug reaction Taking any antioxidant supplement in the last two months Pregnancy, or breastfeeding unwillingness to attend the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Neuropathy intensity. Timepoint: The first day and 3rd month after the onset of the intervention. Method of measurement: Common Terminology Criteria for Adverse Events (CTCAE) criterion and questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Quality of life. Timepoint: The first day and the 3rd month after the start of the intervention. Method of measurement: European Organization for Research and Treatment of Cancer quality of life questionnaire (EORTC QLQ).;Pain intensity. Timepoint: The first day and 3rd month after the start of the intervention. Method of measurement: Visual analysis scale (VAS) criterion and questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Ramin Shekarriz
Mazandaran University of Medical Sciences
Outcome results
None listed